methylcob(III)alamin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases asymmetric dimethylarginine (ADMA) concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The percentage of decrease in ADMA levels was greater in the methylcobalamin than folate group (25.4% +/- 10.2% vs 13.2% +/- 11.2%; P < 0.001).”
Quoted verbatim from Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.. - Study
- RCT
- Duration
- 3 weeks
- Dose
- 500 mcg intravenous methylcobalamin after each hemodialysis treatment, 3 times weekly, plus folate 15 mg/d
- Population
- Maintenance hemodialysis patients; oral folate 15 mg/d given to both arms as background, methylcobalamin added in one arm; 3 weeks, open-label
Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.2010PMID:20430500Permalink
Keep reading
- Everything the graph holds on methylcob(III)alamin
- Every compound studied against Asymmetric dimethylarginine (ADMA) concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4QCQ6C1HVTC1WMS2ZKPEZP9